Table 1. Patient Characteristics (N=40).
| Characteristic | Frequency No. (%) | Numerical Value |
|---|---|---|
| Median age (range), y | 59 (42-78) | |
| Male | 30 (75) | |
| Median no. of prior therapies (range) | 3 (1-8) | |
| Prior fludarabine-based therapy | 36 (90) | |
| Fludarabine-refractory disease | 23 (64) | |
| Prior rituximab-based therapy | 40 (100) | |
| Prior alemtuzumab-based therapy | 4 (10) | |
| Median WBC count, ×109/L (range) | 15.9 (2-265) | |
| Median platelet count, ×109/L (range) | 111 (23-345) | |
| Median hemoglobin levels, g/dL (range) | 12 (8.5-16.3) | |
| Rai stage III and IV | 18 (45) | |
| β-2-microglobulin, mg/dL (range) | 3.9 (1.7-13.6) | |
| ZAP-70-positive | 5/7 (71) | |
| IgVH unmutated | 13/15 (87) | |
| Karyotype | ||
| 17p del | 1/23 (4) | |
| 11q del | 4/23 (17) | |
| + 12 | 2/23 (9) | |
| diploid | 12/23 (52) | |
| 13q del | 1/23 (4) |
WBC indicates white blood cell; IgVH, immunoglobulin heavy chain variable.